phase 2_completion
saveMerck & Co Inc — tulisokibart (Phase II Trial Completion)
community read0 votes
Therapy area: Immunology, Respiratory. Indication: Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease), Systemic Sclerosis (Scleroderma)